Withanoside V

Withanoside V binds tightly to human serum albumin with a K_s of 5.33 × 10⁴ M^-1, and binds to Sudlow's site I (domain IIA) of human serum albumin with a K_s of 4.8 × 10⁴ M^-1, inducing conformational changes in human serum albumin^[1].
Withanoside V (100 μM; 6-72 h) inhibits the aggregation of Aβ (1-42) in vitro and reduces the formation of β-sheet-rich oligomers and fibrils over an incubation period of up to 72 h^[2].
Withanoside V (10-100 μM; 24-48 h) inhibits the viability of SK-N-SH cells with an IC₅₀ of 30.14 μM, and protects SK-N-SH cells from Aβ (1-42)-induced cytotoxic damage^[2].
Withanoside V (15.07 μM; 24 h) increases the proportion of early apoptotic cells in human SK-N-SH neuroblastoma cells while maintaining a high overall cell viability^[2].
Compared with cells treated with Aβ (1-42), Withanoside V (15.07 μM; 24 h) reduces the level of DNA fragmentation and the number of apoptotic cells in human SK-N-SH neuroblastoma cells^[2].
Withanoside V (15.07 μM; 24 h) significantly reduces Aβ (1-42)-induced intracellular ROS production in human SK-N-SH neuroblastoma cells^[2].
Withanoside V is a SARS-CoV-2 M_pro inhibitor with a binding affinity of -8.96 kcal/mol. It forms stable hydrogen bonds at the active site of this enzyme, and its mechanism of action is similar to that of the natural N3 inhibitor^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.